Next Article in Journal
Chinese Herbal Medicine Ganoderma tsugae Displays Potential Anti-Cancer Efficacy on Metastatic Prostate Cancer Cells
Next Article in Special Issue
The Role of Measurable Residual Disease (MRD) in Hematopoietic Stem Cell Transplantation for Hematological Malignancies Focusing on Acute Leukemia
Previous Article in Journal
Reconstitution in Proteoliposomes of the Recombinant Human Riboflavin Transporter 2 (SLC52A2) Overexpressed in E. coli
Previous Article in Special Issue
Immunotherapy-Based Targeting and Elimination of Leukemic Stem Cells in AML and CML
Open AccessReview

Advances in Molecular Biology and Targeted Therapy of Mantle Cell Lymphoma

by Pavel Klener 1,2
1
First Dept. of Medicine-Hematology, General University Hospital in Prague, 128 08 Prague, Czech Republic
2
Institute of Pathological Physiology, First Faculty of Medicine, Charles University, 128 53 Prague, Czech Republic
Int. J. Mol. Sci. 2019, 20(18), 4417; https://doi.org/10.3390/ijms20184417
Received: 15 August 2019 / Revised: 2 September 2019 / Accepted: 4 September 2019 / Published: 8 September 2019
(This article belongs to the Special Issue Advances in Molecular Biology and Targeted Therapy of Leukemias 2.0)
Mantle cell lymphoma (MCL) is a heterogeneous malignancy with a broad spectrum of clinical behavior from indolent to highly aggressive cases. Despite the fact that MCL remains in most cases incurable by currently applied immunochemotherapy, our increasing knowledge on the biology of MCL in the last two decades has led to the design, testing, and approval of several innovative agents that dramatically changed the treatment landscape for MCL patients. Most importantly, the implementation of new drugs and novel treatment algorithms into clinical practice has successfully translated into improved outcomes of MCL patients not only in the clinical trials, but also in real life. This review focuses on recent advances in our understanding of the pathogenesis of MCL, and provides a brief survey of currently used treatment options with special focus on mode of action of selected innovative anti-lymphoma molecules. Finally, it outlines future perspectives of patient management with progressive shift from generally applied immunotherapy toward risk-stratified, patient-tailored protocols that would implement innovative agents and/or procedures with the ultimate goal to eradicate the lymphoma and cure the patient. View Full-Text
Keywords: mantle cell lymphoma; cell cycle; B-cell receptor signaling mantle cell lymphoma; cell cycle; B-cell receptor signaling
Show Figures

Figure 1

MDPI and ACS Style

Klener, P. Advances in Molecular Biology and Targeted Therapy of Mantle Cell Lymphoma. Int. J. Mol. Sci. 2019, 20, 4417.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop